Cationic Antimicrobial Peptides: Issues for Potential Clinical Use
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Many different types of organisms use antimicrobial peptides, typically 20-40 amino acids in length, for defence against infection. Most are capable of rapidly killing a wide range of microbial cells. They have been classified according to their active structures into six extensive groups. It is not yet clear how these peptides kill bacterial cells, but it is widely believed that some cationic antimicrobial peptides kill by disrupting bacterial membranes, allowing the free exchange of intra- and extra-cellular ions. The selectivity of these peptides appears to relate to differences between the external membranes of prokaryotic and eukaryotic cells. The action of the peptides may involve the formation of 'barrel-stave' or 'torroidal' pores, the introduction of packing defects in the membrane phospholipids, or large-scale disruption of the membrane by a very dense aggregation of parallel-oriented peptide, called the 'carpet mechanism'. Antimicrobial peptides are attractive candidates for clinical development because of their selectivity, their speed of action and because bacteria may not easily develop resistance against them. Some antimicrobial peptides are already in clinical and commercial use, including ambicin (nisin), polymixin B and gramicidin S. There have been several attempts at developing peptides to make them more suitable for clinical use. For those peptides that act against bacterial membranes, it is possible to differentiate between those structural features that contribute to the specificity of initial membrane binding and those that contribute to the subsequent breach of membrane integrity. The design of novel antimicrobial peptides would necessitate the optimisation of multiple parameters, a problem that has proved difficult to solve. Potential problems to be overcome include high production costs, toxicity against eukaryotic cells, susceptibility to proteolytic degradation and the development of allergies to the peptides. Biosynthesis, using recombinant DNA techniques, could make commercial-scale synthesis feasible but the peptides are usually lethal to the micro-organisms used to produce them. Proteolytic degradation can be reduced by modifying the peptides to contain nonstandard amino acids, or by restricting the use of peptides to topical applications. The problem of sensitisation could be overcome by the use of our own natural antibiotics to prevent or treat infections. Despite early hopes that bacteria would not easily develop resistance to antimicrobial peptides, it is clear that some strains of bacteria already have.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cryptic AMPs are derived from precursor proteins that may or may not be inherently antimicrobial, and such activity is often attributed to their cationic nature, which disrupts the microbial cell membranes [43].”
From Comparative Genomics-Based Evaluation of Lacticaseibacillus rhamnosus KFOM 0134 as a Probiotic against Staphylococcus aureus (2026) · cites this paper as [43]
Citations
Cites
Zasloff, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5449 · Cited by 2,305
Diversity of antimicrobial peptides and their mechanisms of action
Epand, R. M., & Vogel, H. J. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00198-4 · Cited by 1,358
Amphipathic, α-helical antimicrobial peptides
Tossi, A., Sandri, L., & Giangaspero, A. (2000) · Biopolymers · doi:10.1002/1097-0282(2000)55:1<4::aid-bip30>3.0.co;2-m · Cited by 1,247
Mode of action of linear amphipathic α-helical antimicrobial peptides
Oren, Z., & Shai, Y. (1998) · Biopolymers · doi:10.1002/(sici)1097-0282(1998)47:6<451::aid-bip4>3.0.co;2-f · Cited by 848
Dathe, M., & Wieprecht, T. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00201-1 · Cited by 754
Action of Antimicrobial Peptides: Two-State Model
Huang, H. W. (2000) · Biochemistry · doi:10.1021/bi000946l · Cited by 740 · cited 3×
“However, a common(lantibiotics); peptaibols; and macrocyclic cystine knot peptides. mechanism seems to be that described by Huang,[5] whose ‘two- Some of the best studied antimicrobial peptides fall into Epand state’ model distinguishes between the initial membrane-binding and Vogel’s first group ‘amphipathic and hydr…”
BackgroundLipid A Acylation and Bacterial Resistance against Vertebrate Antimicrobial Peptides
Guo, L., Lim, K. B., Poduje, C. M., Daniel, M., Gunn, J. S., Hackett, M., & Miller, S. I. (1998) · Cell · doi:10.1016/s0092-8674(00)81750-x · Cited by 649
Animal antimicrobial peptides: An overview
Andreu, D., & Rivas, L. (1998) · Biopolymers · doi:10.1002/(sici)1097-0282(1998)47:6<415::aid-bip2>3.0.co;2-d · Cited by 618
Role of membranes in the activities of antimicrobial cationic peptides
Hancock, R. (2002) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(01)00480-3 · Cited by 574 · cited 3×
“Hancock REW, Rozek A. Role of membranes in the activities of antimicrobial 27.”
BackgroundInfluentialRegulation of Lipid A Modifications by Salmonella typhimurium Virulence Genes phoP-phoQ
Guo, L., Lim, K. B., Gunn, J. S., Bainbridge, B., Darveau, R. P., Hackett, M., & Miller, S. I. (1997) · Science · doi:10.1126/science.276.5310.250 · Cited by 559 · cited 1×
“[20] binding or block the transfer of peptides across the outer membrane.[16-18] Tachyplesin I and magainins are known to bind to LPS Polymixin B, a bacteria-derived antimicrobial peptide, is aland also display an affinity for negatively charged phospholipids.”
Background
Research works printed but not linked: 2
- Hancock, 2002, FEMS Microbiol Lett, 206, 143, 10.1111/j.1574-6968.2002.tb11000.x · doi:10.1111/j.1574-6968.2002.tb11000.x · Paper page
- Gellman, 2001, Biophys J, 80, 2d
Cited by
Bahar, A., & Ren, D. (2013) · Pharmaceuticals · doi:10.3390/ph6121543 · Cited by 1,351
Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action
Chan, D. I., Prenner, E. J., & Vogel, H. J. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.04.006 · Cited by 1,039
APD: the Antimicrobial Peptide Database
Wang, Z. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh025 · Cited by 808
Mechanisms and consequences of bacterial resistance to antimicrobial peptides
Andersson, D. I., Hughes, D., & Kubicek-Sutherland, J. Z. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.04.002 · Cited by 715
“…AMPs is also plagued by issues with the nherent instability of peptides, their susceptibility to proteolyic degradation, the cost of peptide production and purification, nd the high association of toxic side effects which have been eviewed previously (Bradshaw, 2003; Marr et al., 2006; Vaara, 009).”
BackgroundA Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs
Gordon, Y. J., Romanowski, E. G., & McDermott, A. M. (2005) · Current Eye Research · doi:10.1080/02713680590968637 · Cited by 697
Metadata
- Authors
- Bradshaw, J. P.
- Affiliations
- University of Edinburgh (GB)
- Corresponding author
- Bradshaw, Jeremy P
- Venue
- BioDrugs
- Published
- 2003
- Volume
- 17
- Issue
- 4
- Pages
- 233-240
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- OpenAlex
- W1487871178
- Cited by
- 293
- References
- 27
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 19 · 2023: 18 · 2022: 16 · 2021: 11 · 2020: 25 · 2019: 17 · 2018: 16 · 2017: 17 · 2016: 11 · 2015: 16 · 2014: 13 · 2013: 16 · 2012: 12
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- BioDrugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cationic antimicrobial peptides, bacterial membrane disruption, peptide-membrane binding, pore formation, carpet mechanism, peptide selectivity, antimicrobial peptide design, peptide toxicity, proteolysis, antimicrobial resistance, nisin, polymyxin B, gramicidin S
- MeSH terms
- Animals, Anti-Bacterial Agents, Forecasting, Humans, Structure-Activity Relationship, Technology, Pharmaceutical, Drug Design, Antimicrobial Cationic Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cationic Antimicrobial Peptides: Issues for Potential Clinical Use. https://app.cochat.ai/papers/10.2165/00063030-200317040-00002
- The paper
- Bradshaw, J. P. (2003). Cationic Antimicrobial Peptides: Issues for Potential Clinical Use. BioDrugs. https://doi.org/10.2165/00063030-200317040-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.